Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Int J Urol. 2006 Nov; 13(11):1405-9.IJ

Abstract

AIM

The objective of the study was to compare the efficacy and safety of tamsulosin hydrochloride and doxazosin in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).

METHODS

The safety and efficacy of tamsulosin (0.2 mg) and doxazosin (2 mg) was determined after once daily administration for 6 weeks in an open-label, randomized, multicenter study of 101 men with BPH. The International Prostatic Symptom Score (IPSS), maximal urinary flow rates (Qmax), average urinary flow rates (Qave) and residual urine were determined at baseline and again at 6 weeks as efficacy parameters. The primary parameters used for safety evaluation were vital signs (blood pressure and heart rate) and adverse events. The number of patients with a clinically significant response to treatment with tamsulosin or doxazosin was determined and defined as those with >20% improvement from the baseline Qmax or >20% decrease in total IPSS.

RESULTS

The total IPSS decreased significantly in both the tamsulosin and doxazosin groups compared to baseline. There was a significant difference in the decrease in total IPSS between two groups. Qmax, Qave and residual urine significantly improved only in the tamsulosin group. There were no significant differences in systolic blood pressure, diastolic blood pressure or heart rate profile in the tamsulosin group; however, doxazosin resulted in a significant difference in systolic and diastolic blood pressure. Tamsulosin was well tolerated; only three patients (6%) in the tamsulosin group reported an adverse event (dizziness) while 11 patients (22%) in the doxazosin group reported an adverse event (dizziness), one of whom withdrew from the study.

CONCLUSIONS

Tamsulosin was shown to be more effective than doxazosin in the treatment of LUTS due to BPH.

Authors+Show Affiliations

Subdivision of Urology, Department of Surgery University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17083392

Citation

Rahardjo, Djoko, et al. "Efficacy and Safety of Tamsulosin Hydrochloride Compared to Doxazosin in the Treatment of Indonesian Patients With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia." International Journal of Urology : Official Journal of the Japanese Urological Association, vol. 13, no. 11, 2006, pp. 1405-9.
Rahardjo D, Soebadi DM, Sugandi S, et al. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Int J Urol. 2006;13(11):1405-9.
Rahardjo, D., Soebadi, D. M., Sugandi, S., Birowo, P., Djati, W., & Wahyudi, I. (2006). Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. International Journal of Urology : Official Journal of the Japanese Urological Association, 13(11), 1405-9.
Rahardjo D, et al. Efficacy and Safety of Tamsulosin Hydrochloride Compared to Doxazosin in the Treatment of Indonesian Patients With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. Int J Urol. 2006;13(11):1405-9. PubMed PMID: 17083392.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. AU - Rahardjo,Djoko, AU - Soebadi,Doddy M, AU - Sugandi,Suwandi, AU - Birowo,Ponco, AU - Djati,Wahjoe, AU - Wahyudi,Irfan, PY - 2006/11/7/pubmed PY - 2007/3/14/medline PY - 2006/11/7/entrez SP - 1405 EP - 9 JF - International journal of urology : official journal of the Japanese Urological Association JO - Int J Urol VL - 13 IS - 11 N2 - AIM: The objective of the study was to compare the efficacy and safety of tamsulosin hydrochloride and doxazosin in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). METHODS: The safety and efficacy of tamsulosin (0.2 mg) and doxazosin (2 mg) was determined after once daily administration for 6 weeks in an open-label, randomized, multicenter study of 101 men with BPH. The International Prostatic Symptom Score (IPSS), maximal urinary flow rates (Qmax), average urinary flow rates (Qave) and residual urine were determined at baseline and again at 6 weeks as efficacy parameters. The primary parameters used for safety evaluation were vital signs (blood pressure and heart rate) and adverse events. The number of patients with a clinically significant response to treatment with tamsulosin or doxazosin was determined and defined as those with >20% improvement from the baseline Qmax or >20% decrease in total IPSS. RESULTS: The total IPSS decreased significantly in both the tamsulosin and doxazosin groups compared to baseline. There was a significant difference in the decrease in total IPSS between two groups. Qmax, Qave and residual urine significantly improved only in the tamsulosin group. There were no significant differences in systolic blood pressure, diastolic blood pressure or heart rate profile in the tamsulosin group; however, doxazosin resulted in a significant difference in systolic and diastolic blood pressure. Tamsulosin was well tolerated; only three patients (6%) in the tamsulosin group reported an adverse event (dizziness) while 11 patients (22%) in the doxazosin group reported an adverse event (dizziness), one of whom withdrew from the study. CONCLUSIONS: Tamsulosin was shown to be more effective than doxazosin in the treatment of LUTS due to BPH. SN - 0919-8172 UR - https://www.unboundmedicine.com/medline/citation/17083392/Efficacy_and_safety_of_tamsulosin_hydrochloride_compared_to_doxazosin_in_the_treatment_of_Indonesian_patients_with_lower_urinary_tract_symptoms_due_to_benign_prostatic_hyperplasia_ L2 - https://doi.org/10.1111/j.1442-2042.2006.01590.x DB - PRIME DP - Unbound Medicine ER -